EMD Millipore Expands its Emprove Raw Materials Portfolio - - BioPharm International

ADVERTISEMENT

EMD Millipore Expands its Emprove Raw Materials Portfolio



EMD Millipore, the life-science division of Merck KGaA, reported the expansion of its Emprove raw materials portfolio to 400 APIs, excipients, and biopharmaceutical materials. The products offer detailed application-specific documentation in addition to increased quality, allowing pharmaceutical manufacturers to reduce qualification costs and accelerate time-to-market processes, according to the company.

The portfolio includes Emprove api for APIs, Emprove exp for excipients, and Emprove bio for biopharmaceutical materials, which provide the documentation to improve transparency and efficiency. The revised documentation, prepared in an internationally accepted format, prevents errors from gathering information manually and minimizes risk to patients, according to the company.

Depending on the application, the Emprove documentation can contain information regarding manufacturer and manufacturing process details, testing procedures, purity, and stability data. The APIs are manufactured according to cGMP guideline ICH Q7, the excipients are EXCiPACT certified, and the biopharmaceutical materials can be used in both upstream and downstreamprocess steps.

Source: EMD Millipore
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here